Hemostemix Reports 83% Success Rate in Phase II Trial, Seeks OTCQB Up-listing
Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) is advancing its market presence through an OTCQB Venture Market up-listing application, while simultaneously reporting impressive clinical outcomes for its flagship ACP-01 therapy. The strategic move aims to enhance liquidity across North American and European markets.
Breakthrough Clinical Results
The company's Phase II clinical trial has yielded remarkable results in treating various vascular conditions. In a long-term study spanning 4.5 years, 83% of patients experienced successful healing of ulcers and resolution of ischemic rest pain. The therapy demonstrated particular efficacy in treating dilated cardiomyopathy, where patients showed cardiac function improvements of up to 47.1% following a single treatment.
Notably, the Phase II results revealed statistically significant ulcer reduction, with mean ulcer size decreasing from 1.46 cm² to 0.48 mm² within three months (p = 0.01). These outcomes are particularly significant given the severity of conditions being treated.
Addressing Critical Market Needs
The therapeutic potential of ACP-01 addresses a substantial global health challenge. Currently, 236 million people worldwide suffer from peripheral arterial disease (PAD), with 23 million developing chronic limb threatening ischemia (CLTI). The severity of these conditions is underscored by a sobering 60% five-year mortality rate for CLTI patients.
Innovative Treatment Approach
ACP-01 represents a personalized medicine approach, utilizing patients' own blood and serum for treatment. Thomas Smeenk, CEO of Hemostemix, emphasized the therapy's potential impact: "Our testimonials connect ACP-01-treated patients with the millions of no-option patients who may obtain an ACP treatment under special access program."
The company's therapeutic platform, which earned the World Economic Forum Technology Pioneer Award, encompasses various cell precursor technologies, including angiogenic, neuronal, and cardiomyocyte cell precursors. This comprehensive approach positions Hemostemix at the forefront of regenerative medicine for vascular and cardiac conditions.
Market Expansion Strategy
The pending OTCQB up-listing represents a strategic move to increase market accessibility and trading liquidity. This expansion is supported by an active social media campaign across major platforms, sharing patient success stories and treatment outcomes. The company's presence on Instagram, Facebook, LinkedIn, YouTube, and X has been instrumental in communicating the real-world impact of their therapeutic solutions.